Eye Infections, Bacterial

5
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Thea Pharma
Thea PharmaMA - Waltham
5 programs
5
AzithromycinPhase 11 trial
AzithromycinPhase 11 trial
AzithromycinPhase 11 trial
AzithromycinPhase 11 trial
AzithromycinPhase 11 trial
Active Trials
NCT00357383CompletedEst. Oct 2002
NCT00356850CompletedEst. Jun 2002
NCT00357539CompletedEst. Mar 2002
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Thea PharmaAzithromycin
Thea PharmaAzithromycin
Thea PharmaAzithromycin
Thea PharmaAzithromycin
Thea PharmaAzithromycin

Clinical Trials (5)

Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers

Start: Feb 2003Est. completion: Mar 2003
Phase 1Completed

Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers

Start: Oct 2002Est. completion: Oct 2002
Phase 1Completed

Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers

Start: May 2002Est. completion: Jun 2002
Phase 1Completed

Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers

Start: Mar 2002Est. completion: Apr 2002
Phase 1Completed

Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers

Start: Feb 2002Est. completion: Mar 2002
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space